https://clinicaltrials.gov/ct2/show...b&cond=Glioblastoma&draw=2&rank=3Detailed Description:
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. Its goals are to identify effective therapies for glioblastoma and match effective therapies with patient subtypes. Bayesian response adaptive randomization is used within subtypes of the disease to assign participants to Arms based on their performance. The primary endpoint is overall survival (OS).
GBM AGILE is designed to efficiently evaluate therapies. The trial will be conducted under a single Master Investigational New Drug Application/Clinical Trial Application and Master Protocol, allowing multiple drugs and drug combinations from different pharmaceutical companies to be evaluated simultaneously. The plan is to add experimental therapies as new information about promising new drugs are identified and remove therapies as they complete their evaluation.
Study Design
| Study Type : | Interventional (Clinical Trial) |
|---|
| 1 | Estimated Enrollment : | 1030 participants |
|---|
| 2 | Allocation: | Randomized |
|---|
| 3 | Intervention Model: | Sequential Assignment |
|---|
| 4 | Intervention Model Description: | GBM AGILE is a multi-arm, platform trial. The evaluation of each therapy in GBM AGILE proceeds in 2 possible stages. A therapy's Stage 1 is an adaptively randomized Screening stage for evaluating the therapy within patient signatures compared against a common control. A therapy in Stage 1 will stop accruing patients if it reaches its maximal sample size, drops for futility, or evinces inadequate safety. If a therapy reaches an efficacy threshold for graduation from Stage 1, it will move into Stage 2 within one of the prospectively defined signatures. The maximum sample size in Stage 1 is 150 patients.
For a therapy graduating to Stage 2 there is a fixed randomization, expansion cohort. The maximum sample size in Stage 2 is 50 experimental patients in the graduating signature. The primary analysis of a regimen's effect on OS uses all patients in both its stages and all control patients in the trial in the graduating signature, suitably adjusted for any possible time trends. |
|---|
| 5 | Masking: | None (Open Label) |
|---|
| 6 | Primary Purpose: | Treatment |
|---|
| 7 | Official Title: | GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM |
|---|
| 8 | Actual Study Start Date : | July 30, 2019 |
|---|
| 9 | Estimated Primary Completion Date : | June 2026 |
|---|
| 10 | Estimated Study Completion Date : | June 2028 |
|---|
"A therapy in Stage 1 will stop accruing patients if it reaches its maximal sample size, drops for futility, or evinces inadequate safety."
OK. So it reached maximal sample size it stopped recruiting. But it isn't going on to stage 2... so either safety was inadequate (severe side effects) or it didn't work well enough that it was going to show statistical evidence of efficacy (futility).
My bet is on futility.
